Goldman Sachs analyst Matthew Sykes downgraded Nautilus Biotechnology (NAUT) to Sell from Neutral with a $1.75 price target which represents 21% downside to the current stock price. The firm believes the market for discovery proteomics has become more competitive with innovation from mass spec players, as Nautilus’ instrument launch timeline has been pushed out over time.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NAUT:
- Nautilus Biotechnology Faces ESG Challenges Amid Regulatory Pressure and Investor Scrutiny
- Nautilus Biotechnology Reports Q3 2024 Financial Results
- Nautilus Biotechnology reports Q3 EPS (13c), consensus (16c)
- Nautilus Biotechnolgy, Inc. (NAUT) Q3 Earnings Cheat Sheet
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
